Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, Rubas W, Doberstein SK, Eldon M, Hoch U, Zalevsky J. Charych D, et al. Among authors: langowski j. PLoS One. 2017 Jul 5;12(7):e0179431. doi: 10.1371/journal.pone.0179431. eCollection 2017. PLoS One. 2017. PMID: 28678791 Free PMC article.
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, Sheng D, Liu X, Sims PW, VanderVeen LA, Ali CF, Chang TK, Konakova M, Pena RL, Kanhere RS, Kirksey YM, Ji C, Wang Y, Huang J, Sweeney TD, Kantak SS, Doberstein SK. Charych DH, et al. Among authors: langowski jl. Clin Cancer Res. 2016 Feb 1;22(3):680-90. doi: 10.1158/1078-0432.CCR-15-1631. Clin Cancer Res. 2016. PMID: 26832745
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases.
Dixit N, Fanton C, Langowski JL, Kirksey Y, Kirk P, Chang T, Cetz J, Dixit V, Kim G, Kuo P, Maiti M, Tang Y, VanderVeen LA, Zhang P, Lee M, Ritz J, Kamihara Y, Ji C, Rubas W, Sweeney TD, Doberstein SK, Zalevsky J. Dixit N, et al. Among authors: langowski jl. J Transl Autoimmun. 2021 May 6;4:100103. doi: 10.1016/j.jtauto.2021.100103. eCollection 2021. J Transl Autoimmun. 2021. PMID: 34041473 Free PMC article.
IL-10 elicits IFNγ-dependent tumor immune surveillance.
Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, Sheppard C, Hong K, Cutler C, Turner S, LaFace D, Kleinschek M, Judo M, Ayanoglu G, Langowski J, Gu D, Paporello B, Murphy E, Sriram V, Naravula S, Desai B, Medicherla S, Seghezzi W, McClanahan T, Cannon-Carlson S, Beebe AM, Oft M. Mumm JB, et al. Among authors: langowski j. Cancer Cell. 2011 Dec 13;20(6):781-96. doi: 10.1016/j.ccr.2011.11.003. Cancer Cell. 2011. PMID: 22172723 Free article.
IL-23 promotes tumour incidence and growth.
Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M. Langowski JL, et al. Nature. 2006 Jul 27;442(7101):461-5. doi: 10.1038/nature04808. Epub 2006 May 10. Nature. 2006. PMID: 16688182
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
Poddutoori R, Aardalen K, Aithal K, Barahagar SS, Belliappa C, Bock M, Chelur S, Gerken A, Gopinath S, Gruenenfelder B, Kiffe M, Krishnaswami M, Langowski J, Madapa S, Narayanan K, Pandit C, Panigrahi SK, Perrone M, Potakamuri RK, Ramachandra M, Ramanathan A, Ramos R, Sager E, Samajdar S, Subramanya HS, Thimmasandra DS, Venetsanakos E, Möbitz H. Poddutoori R, et al. Among authors: langowski j. J Med Chem. 2022 Mar 10;65(5):4350-4366. doi: 10.1021/acs.jmedchem.1c02192. Epub 2022 Feb 23. J Med Chem. 2022. PMID: 35195996
In the soft grip of nature.
Langowski JKA, Sharma P, Shoushtari AL. Langowski JKA, et al. Sci Robot. 2020 Dec 16;5(49):eabd9120. doi: 10.1126/scirobotics.abd9120. Sci Robot. 2020. PMID: 33328299
203 results